Arecor Collaborates with Global Technology Leader

RNS Number : 5101V

Arecor Therapeutics PLC

14 December 2021

Arecor Therapeutics plc

("Arecor" or the "Group")

ARECOR ANNOUNCES EXCLUSIVE COLLABORATION WITH GLOBAL TECHNOLOGY LEADER

Development of a stable liquid formulation for use within partner's technology

Cambridge, UK, 14 December 2021: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that it has signed an exclusive formulation study collaboration.

The partner is a global technology leader, serving customers across research, clinical and applied markets. Under the terms of the agreement, Arecor will use its proprietary formulation technology platform, Arestat™, to develop an improved, stable, liquid formulation for use within their technology. The partner will fund the development work and has the option to acquire the rights to the new proprietary formulation and associated Intellectual Property under a technology licensing model to further develop and commercialise the product.

Sarah Howell, Chief Executive Officer of Arecor, said: "We continue to expand the multiple potential applications of our innovative Arestat™ platform. Supporting our partner's molecular testing platform augments our portfolio, showcasing the breadth of our technology platform's potential. Our partner's products are used for applications in life sciences, oncology, reproductive health, agriculture and other emerging segments, expanding our reach into new markets. We look forward to working with them and advancing our Arestat™ platform in the diagnostic space to support personalised medicine for patients."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

-ENDS-

For more information, please contact:

Arecor Therapeutics plc	www.arecor.com
Dr Sarah Howell, Chief Executive Officer	Tel: +44 (0) 1223 426060 Email: [email protected]

Susan Lowther, Chief Financial Officer	Tel: +44 (0) 1223 426060 Email: [email protected]

Mo Noonan, Communications	Tel: +44 (0) 7876 444977 Email: [email protected]

Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking)	Tel: +44 (0) 20 7886 2500

Consilium Strategic Communications
Chris Gardner, David Daley, Angela Gray	Tel: +44 (0) 20 3709 5700 Email: [email protected]

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.

For further details please see our website, www.arecor.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCTJBMTMTMBTIB